Columbia University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1754-01-01

Employees: 20.8K

Market Cap: -

Website: https://www.arch.columbia.edu

Clinical Trials

Hypothermic Machine Preservation-Phase 2

Not Applicable

Completed

Conditions: Liver Damage

Interventions: Device: The Medtronic Portable Bypass System (PBS®)

First Posted Date: 2011-01-11

Last Posted Date: 2020-07-27

Lead Sponsor: Columbia University

Target Recruit Count: 24

Registration Number: NCT01274520

Locations: 🇺🇸
Columbia University, New York, New York, United States

Use of Pulsed Electromagnetic Fields (PEMF) After Breast Reconstruction Surgery

Phase 4

Completed

Conditions: Other Reconstructive Surgery

Interventions: Device: Ivivi Torino II PEMF Device
Device: Sham PEMF Device

First Posted Date: 2010-12-17

Last Posted Date: 2018-09-25

Lead Sponsor: Columbia University

Target Recruit Count: 32

Registration Number: NCT01262599

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

Measuring Adherence to Control Hypertension

Not Applicable

Completed

Conditions: Hypertension

Interventions: Device: MedSignals pillbox
Behavioral: Disclosure of adherence report to clinician

First Posted Date: 2010-12-09

Last Posted Date: 2017-04-05

Lead Sponsor: Columbia University

Target Recruit Count: 124

Registration Number: NCT01257347

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

Pulsed Electromagnetic Fields (PEMF) and Post-Axillary Surgery Morbidity

Phase 4

Terminated

Conditions: Shoulder Symptoms After Lymph Node Dissection

Interventions: Device: Sham PEMF Device
Device: PEMF Device

First Posted Date: 2010-12-07

Last Posted Date: 2015-10-16

Lead Sponsor: Columbia University

Target Recruit Count: 22

Registration Number: NCT01255631

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease

Phase 2

Completed

Conditions: Hypertension
End Stage Renal Disease

Interventions: Drug: Vasopressin - Very Low Dose
Drug: Vasopressin - Low Dose
Drug: Placebo Comparator

First Posted Date: 2010-11-24

Last Posted Date: 2019-11-18

Lead Sponsor: Columbia University

Target Recruit Count: 12

Registration Number: NCT01247090

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

High-Tc Susceptometer to Monitor Transfusional Iron Overload

Completed

Conditions: Transfusional Iron Overload
Sickle Cell Disease
Aplastic Anemia
Myelodysplastic Syndromes
Thalassemia Major

Interventions: Device: Hepatic biomagnetic susceptibility measurement

First Posted Date: 2010-11-16

Last Posted Date: 2016-09-21

Lead Sponsor: Columbia University

Target Recruit Count: 99

Registration Number: NCT01241357

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

Drug Abuse Prevention Among Girls Through a Mother-Daughter Intervention

Not Applicable

Completed

Conditions: Substance Use

Interventions: Behavioral: Prevention

First Posted Date: 2010-11-07

Last Posted Date: 2017-07-18

Lead Sponsor: Columbia University

Target Recruit Count: 916

Registration Number: NCT01236248

Locations: 🇺🇸
Columbia University, New York, New York, United States

Real-time Influenza Vaccine Surveillance

Completed

Conditions: Vaccine Safety

Interventions: Other: Text message surveillance

First Posted Date: 2010-11-03

Last Posted Date: 2012-06-12

Lead Sponsor: Columbia University

Target Recruit Count: 400

Registration Number: NCT01233388

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis

Phase 2

Completed

Conditions: AL Amyloidosis

Interventions: Drug: Bendamustine
Drug: Dexamethasone

First Posted Date: 2010-10-18

Last Posted Date: 2020-03-30

Lead Sponsor: Columbia University

Target Recruit Count: 40

Registration Number: NCT01222260

Locations: 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Columbia University, New York, New York, United States

and more 3 locations

Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy

Phase 1

Completed

Conditions: Dense Deposit Disease
Membranoproliferative Glomerulonephritis

Interventions: Drug: Eculizumab

First Posted Date: 2010-10-14

Last Posted Date: 2019-02-19

Lead Sponsor: Columbia University

Target Recruit Count: 6

Registration Number: NCT01221181

Locations: 🇺🇸
Columbia University Medical Center, Nephrology Clinical Research Center, New York, New York, United States
🇺🇸
Columbia University Medical Center, Glomerular Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy